Attributes | Values |
---|
rdf:type
| |
http://linked.open...gbank/description
| - Dapoxetine is a selective serotonin reuptake inhibitor, for the treatment of premature ejaculation. In a phase II proof-of-concept study conducted by PPD, dapoxetine demonstrated a statistically significant increase in ejaculatory latency when compared to placebo. Alza submitted a NDA to the FDA for dapoxetine for the treatment of premature ejaculation in December 2004. In October 2005, the company received a FDA Non-Approvable letter from the FDA, at which time they planned to work with regulators to address outstanding questions. (en)
|
http://linked.open...generalReferences
| - # Safarinejad MR: Safety and Efficacy of Dapoxetine in the Treatment of Premature Ejaculation: A Double-Blind, Placebo-Controlled, Fixed-Dose, Randomized Study. Neuropsychopharmacology. 2007 Jul 11;. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17625501 # Cirillo-Penn K, Modi NB: Dapoxetine and Paroxetine for the Treatment of Premature Ejaculation. Clin Neuropharmacol. 2007 September/October;30(5):315. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17909314 # McMahon C: Dapoxetine in the treatment of premature ejaculation. Clin Neuropharmacol. 2007 Sep-Oct;30(5):314-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17909313 # Wang WF, Chang L, Minhas S, Ralph DJ: Selective serotonin reuptake inhibitors in the treatment of premature ejaculation. Chin Med J (Engl). 2007 Jun 5;120(11):1000-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17624269 # Pryor JL, Althof SE, Steidle C, Rosen RC, Hellstrom WJ, Shabsigh R, Miloslavsky M, Kell S: Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet. 2006 Sep 9;368(9539):929-37. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16962882 # Hellstrom WJ, Heintz JW: Treatment of premature ejaculation: new drugs and treatment strategies. Curr Urol Rep. 2006 Nov;7(6):473-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17052444 # Modi NB, Dresser M, Desai D, Edgar C, Wesnes K: Dapoxetine has no pharmacokinetic or cognitive interactions with ethanol in healthy male volunteers. J Clin Pharmacol. 2007 Mar;47(3):315-22. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17322143 # Payne RE, Sadovsky R: Identifying and treating premature ejaculation: importance of the sexual history. Cleve Clin J Med. 2007 May;74 Suppl 3:S47-53. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17546831 (en)
|
http://linked.open...gy/drugbank/group
| |
http://linked.open...drugbank/halfLife
| - Initial half-life of 1-2 hours. (en)
|
http://linked.open...ugbank/indication
| - For the treatment of premature ejaculation. (en)
|
sameAs
| |
Title
| |
adms:identifier
| |
http://linked.open...mechanismOfAction
| - The drug's mechanism of action is thought to be related to inhibition of neuronal reuptake of serotonin and subsequent potentiation of serotonin activity. The central ejaculatory neural circuit comprises spinal and cerebral areas that form a highly interconnected network. The sympathetic, parasympathetic, and somatic spinal centers, under the influence of sensory genital and cerebral stimuli integrated and processed at the spinal cord level, act in synergy to command physiologic events occurring during ejaculation. Experimental evidence indicates that serotonin (5-HT), throughout brain descending pathways, exerts an inhibitory role on ejaculation. To date, three 5-HT receptor subtypes (5-HT(1A), 5-HT(1B), and 5-HT(2C)) have been postulated to mediate 5-HT's modulating activity on ejaculation. (en)
|
http://linked.open.../drugbank/synonym
| - Dapoxetina (en)
- Dapoxetinum (en)
|
http://linked.open...ugbank/IUPAC-Name
| |
http://linked.open...gy/drugbank/InChI
| |
http://linked.open...Molecular-Formula
| |
http://linked.open.../Molecular-Weight
| |
http://linked.open...noisotopic-Weight
| |
http://linked.open...y/drugbank/SMILES
| |
http://linked.open.../Water-Solubility
| |
http://linked.open...ogy/drugbank/logP
| |
http://linked.open...ogy/drugbank/logS
| |
http://linked.open...l/drug/hasATCCode
| |
http://linked.open...nd-Acceptor-Count
| |
http://linked.open...-Bond-Donor-Count
| |
http://linked.open...drugbank/InChIKey
| |
http://linked.open...urface-Area--PSA-
| |
http://linked.open...nk/Polarizability
| |
http://linked.open...bank/Refractivity
| |
http://linked.open...atable-Bond-Count
| |
http://linked.open...ugbank/absorption
| |
http://linked.open.../affectedOrganism
| - Humans and other mammals (en)
|
http://linked.open...casRegistryNumber
| |
http://linked.open...drugbank/category
| |
http://linked.open...k/Bioavailability
| |
http://linked.open...bank/Ghose-Filter
| |
http://linked.open...nk/MDDR-Like-Rule
| |
http://linked.open...k/Number-of-Rings
| |
http://linked.open...siological-Charge
| |
http://linked.open...bank/Rule-of-Five
| |
http://linked.open...tional-IUPAC-Name
| |
http://linked.open...-strongest-basic-
| |